--- title: 'Associate Director, SEC Reporting & Technical Accounting at Vaxcyte' canonical: 'https://feeny.ai/job/associate-director-sec-reporting-technical-accounting-vaxcyte-san-carlos-53e1zk8jnq0t' type: 'job' last_seen: '2026-09-14' --- # Associate Director, SEC Reporting & Technical Accounting at Vaxcyte - **Company:** Vaxcyte - **Location:** San Carlos California, United States - **Posted:** 2026-02-26 - **Last confirmed live:** 2026-09-14 - **Apply:** https://boards.greenhouse.io/vaxcyte/jobs/5126186008?gh_jid=5126186008 ## Job description Join our Mission to Protect Humankind! Vaxcyte is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, which have serious and costly health consequences when left unchecked. Working to eradicate or treat bacterial infections such as invasive pneumococcal disease, Group A Strep, and Shigella is just the beginning. Our path to success is clear and well-defined, and Vaxcyte is set up to go the distance. WHAT we do is every bit as important as HOW we do it! Our work together is guided by four enduring core values: *RETHINK CONVENTION: We bring creative and intellectual diversity to every facet of the work we do in order to innovate and re-innovate the way vaccines are delivered. *AIM HIGH: We embody our collectively audacious goal to courageously make the most complex biologics ever attempted to protect humankind. *LEAD WITH HEART: Everyone leads at Vaxcyte with a kindness-first, inclusive approach to collaboration and vigorous debate that advances our business objectives. *MODEL EXCELLENCE:  The magnitude of our challenge requires our shared commitment to demonstrating integrity, accountability, equality and clarity across communications and decision making. Summary: The Associate Director, SEC Reporting & Technical Accounting will serve as a key contributor to the company’s external reporting and technical accounting function. Reporting to the Senior Director, Technical Accounting & SEC Reporting, this role will be highly hands-on, owning the preparation and execution of SEC filings and technical accounting analyses while also managing one direct report. This role is ideal for a technically strong accounting professional who enjoys operating in the details, partnering cross-functionally, and helping build processes in a growing public biotechnology company. Essential Functions: SEC Reporting (Hands-On Execution) - Own the preparation of quarterly and annual SEC filings, including Forms 10-Q, 10-K, and 8-K - Prepare and/or review primary financial statements, footnotes, and related disclosures in accordance with U.S. GAAP and SEC requirements - Draft and support MD&A disclosures, with emphasis on R&D, G&A, stock-based compensation, and other pre-revenue biotech-specific areas - Coordinate the quarterly close-to-reporting process across Accounting, FP&A, Legal, and external auditors - Support earnings release tie-outs and disclosure controls Technical Accounting - Support technical accounting assessments and documentation for complex transactions, including: - Collaboration, licensing, and R&D-related arrangements - Equity and equity-linked financing transactions - Other complex and other non-routine transactions - Research new accounting standards and SEC guidance; assess applicability and implementation impact - Draft clear, well-supported technical accounting memos and communicate conclusions to stakeholders - Strong experience in ASC 842, including the identification, classification, and accounting of lease arrangements, as well as the preparation and review of related disclosures in compliance with U.S. GAAP People Management - Manage and mentor one direct report, providing coaching, review, and development support - Review work products to ensure accuracy, quality, and adherence to timelines - Foster strong execution discipline and continuous improvement within the reporting function Process Improvement & Scaling - Help design and enhance scalable SEC reporting and technical accounting processes as the company grows - Partner with cross-functional teams to ensure accounting and reporting considerations are incorporated into business decisions - Support SOX and internal control documentation related to SEC reporting and technical accounting as applicable Requirements: Bachelor’s degree in Accounting or related field; CPA strongly preferred with a minimum 10 years of progressive accounting experience, including: Public accounting experience (Big 4 or national firm strongly preferred) and/or direct SEC reporting experience at a public company.  Other combinations of education and/or experience may be considered. - Strong technical knowledge of U.S. GAAP and SEC reporting requirements - Excellent written and verbal communication skills - Highly detail-oriented with strong execution skills - Comfortable operating in a fast-paced, evolving environment - Strong ownership mindset with the ability to balance deadlines and quality - Collaborative, proactive, and solutions-oriented - Ability to work onsite 3 days per week required; and more often based on business needs. Location: San Carlos, CA Work Arrangement (may be adjusted based on business needs, job responsibilities, or changes to company policy): Hybrid (3 days per week onsite) Compensation: The compensation package will be competitive and includes comprehensive benefits and an equity component. Salary Range: $184,000 - $215,000 (SF Bay Area). Salary ranges for non-California locations may vary. ## Equal Opportunity We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status. Recruitment Fraud Notice Please be aware of fraud or scams from individuals, organizations and/or internet sites claiming to represent Vaxcyte in recruitment activities. Vaxcyte has an established recruitment process for all positions prior to issuing an offer for employment and we will never extend unsolicited employment offers or ask candidates to provide financial or sensitive personal information as part of the application process. All legitimate communication from Vaxcyte will come from an official @vaxcyte.com email address. Qualified and interested candidates should apply to current openings at [vaxcyte.com/careers](https://vaxcyte.com/careers/). ## About Vaxcyte ## Company Overview - **One-liner**: Vaxcyte is a clinical-stage biotechnology company re-engineering how vaccines are made to eliminate bacterial infections, using a cell-free protein synthesis platform to develop high-fidelity, broad-spectrum vaccines. - **Entity Type**: Public (Ticker: PCVX) - **Headquarters**: San Carlos, California, United States - **Founded**: 2013 (as SutroVax; rebranded to Vaxcyte in 2020) - **Founders**: Not publicly available (the company emerged from Sutro Biopharma’s spin-out) ## Core Business - **Primary industry**: Biotechnology / Vaccines (Infectious Disease) - **Target customers**: Global healthcare systems, public health organizations, and ultimately patients (B2B/Institutional); the company develops vaccines for both pediatric and adult populations. - **Mission or purpose**: To protect humankind from the consequences of bacterial infections, eliminating diseases like invasive pneumococcal disease, Group A Strep, and Shigella. ## Products & Services - **VAX-31 (31-valent PCV)**: A broad-spectrum pneumococcal conjugate vaccine candidate in Phase 3 for adults and Phase 2 for infants. Designed to cover over 95% of circulating IPD serotypes in U.S. adults 50+ and ~94% in infants. FDA Breakthrough Therapy designation granted. - **VAX-24 (24-valent PCV)**: A pneumococcal conjugate vaccine candidate in Phase 2 for infants, designed to cover more serotypes than any infant PCV on the market today. - **VAX-A1 (Group A Strep)**: A preclinical conjugate vaccine candidate for Group A Strep, a disease with no currently approved vaccine. Phase 1 first-in-human study (adults) underway in Australia. - **VAX-GI (Shigella)**: A novel preclinical vaccine candidate targeting Shigella, a leading cause of diarrheal disease. - **Platform Technology**: A proprietary cell-free protein synthesis platform that enables site-specific, carrier-sparing conjugation to produce precisely targeted vaccines with enhanced immunogenicity. ## Market Standing - **Valuation/Market Cap**: ~$16.7 billion (as of early July 2026) - **Key Metric**: Total funding raised (private) is not applicable; as a public company, key metrics include cash position (~$2.0 billion as of Q1 2026) and R&D investment. The company is pre-revenue. - **Notable Investors/Partners**: Major institutional investors include Baker Bros. Advisors, Fidelity, and funds managed by BlackRock. Key partnership: exclusive license agreement with Sutro Biopharma for its cell-free protein synthesis platform. - **Growth Signals**: - Up to $1 billion commitment to expanding U.S. manufacturing with a new facility in North Carolina. - VAX-31 Phase 3 program (OPUS-1, OPUS-2, OPUS-3) topline data expected Q4 2026 – H1 2027. - Headcount growth: actively hiring across 100+ roles (Analytical, Commercial, Clinical, Conjugation, Quality, Regulatory). - Recognized as a Great Place to Work and Best Workplace in BioPharma (multiple years). ## Competitive Advantages - **Broadest-spectrum PCV candidates**: VAX-31 is the broadest-spectrum pneumococcal conjugate vaccine in the clinic, targeting up to 31 serotypes. - **Differentiated platform**: Cell-free protein synthesis allows for the creation of complex, high-fidelity vaccines that can overcome bacterial defense mechanisms (e.g., capsule-switching) that limit conventional cell-based vaccines. - **Carrier-sparing technology**: Site-specific conjugation enables a higher valency (more serotypes) without compromising immunogenicity or tolerability. - **Manufacturing scale**: Significant investment in U.S.-based production capacity provides a long-term supply chain advantage and aligns with "Investing in America" initiatives. ## Strategic Focus - **Primary**: Advance VAX-31 and VAX-24 through late-stage clinical trials to secure regulatory approval and establish a new standard of care for pneumococcal disease. - **Pipeline expansion**: Advance VAX-A1 (Group A Strep) and VAX-GI (Shigella) candidates through early clinical development. - **Manufacturing**: Scale up internal manufacturing capabilities to support commercial launch and global supply. - **Commercial readiness**: Building a commercial organization (e.g., hiring a VP of U.S. Market Access & Pricing, Senior Director of Product Launch) to prepare for potential VAX-31 launch. ## Why Work Here - **Culture**: Described as a "kindness-first" mindset with a focus on audacious goals, collaboration, and mutual support. Recognized as a *Great Place to Work* and *Best Workplace in BioPharma* (Fortune). - **Work Model**: Hybrid, Remote, and Onsite options available depending on role. San Carlos HQ offers a hybrid schedule. - **Total Rewards**: 100% paid health, dental, and vision insurance; 401k matching; flexible PTO and holidays; paid parental and sick leave; equity awards (stock options & RSUs); Employee Stock Purchase Plan; lifestyle spending account; mental health and wellness resources. - **Growth & Development**: Strong emphasis on learning culture, professional advancement through coaching, and career development programs. - **Mission-driven**: Employees are directly contributing to creating vaccines that protect every child born and every adult at risk from bacterial infections globally. ## Sources 1. [vaxcyte.com](https://vaxcyte.com/) 2. [vaxcyte.com/careers](https://vaxcyte.com/careers/) 3. [vaxcyte.com/job-listings](https://vaxcyte.com/job-listings/) 4. [vaxcyte.com/culture](https://vaxcyte.com/culture/) 5. [vaxcyte.com/pipeline](https://vaxcyte.com/pipeline/) ## Other roles at Vaxcyte - [Senior Bioprocess Engineer II, MSAT, Proteins](https://feeny.ai/job/senior-bioprocess-engineer-ii-msat-proteins-vaxcyte-visp-valais-sfkyafmqg7tb) — Visp Valais, Switzerland - [Commercial Project Manager](https://feeny.ai/job/commercial-project-manager-vaxcyte-san-carlos-california-yh8r45mh59a6) — San Carlos California, United States - [Scientist II, Analytical Development (Contract)](https://feeny.ai/job/scientist-ii-analytical-development-contract-vaxcyte-san-carlos-california-b83zc60zvhs3) — San Carlos California, United States - [Lab Compliance Manager](https://feeny.ai/job/lab-compliance-manager-vaxcyte-san-carlos-california-znaqawfbg3r6) — San Carlos California, United States - [Staff Engineer, Process Development and Manufacturing](https://feeny.ai/job/staff-engineer-process-development-and-manufacturing-vaxcyte-san-carlos-bhp8b915gpmn) — San Carlos California, United States - [Manager, Supplier & Internal Auditor](https://feeny.ai/job/manager-supplier-internal-auditor-vaxcyte-san-carlos-california-zshqy3z2ptnp) — San Carlos California, United States - [Senior Manager, Immunoassay Development](https://feeny.ai/job/senior-manager-immunoassay-development-vaxcyte-san-carlos-california-w23kqwk0742d) — San Carlos California, United States - [Lab Manager, Immunoassay Development](https://feeny.ai/job/lab-manager-immunoassay-development-vaxcyte-san-carlos-california-hhgxc5d71egf) — San Carlos California, United States - [Associate Scientist II, Immunoassay Development](https://feeny.ai/job/associate-scientist-ii-immunoassay-development-vaxcyte-san-carlos-california-ems6zhtbe7aj) — San Carlos California, United States - [Scientist, Immunoassay Development](https://feeny.ai/job/scientist-immunoassay-development-vaxcyte-san-carlos-california-datkfkv3dcne) — San Carlos California, United States